<!DOCTYPE html>
<html lang='en'>
<head>
<meta charset='utf-8'><meta name='viewport' content='width=device-width,initial-scale=1'>
<title>Tables Viewer v2.1</title>
<style>:root{--main-header-height:56px;} .table-wrapper{opacity:0;min-height:24px;transition:opacity .12s linear}</style>
<link rel="stylesheet" href="assets/style.css?v=1769960840">
<link rel="stylesheet" href="assets/overrides.css?v=1771658208">
</head><body>
<div id="tables-viewer" role="region" aria-label="Tables viewer">
<div id="stickyMainHeader">
<div id="tv-header">
<div><h1>Tables Viewer v2.1</h1></div>
<div style="display:flex;gap:8px;align-items:center;">
<input id="searchBox" class="tv-search" type="search" placeholder="Search" aria-label="Search tables" />
<button id="modeBtn" type="button" onclick="toggleMode()" aria-label="Toggle theme">Theme</button>
<button id="toggleAllBtn" type="button" aria-label="Toggle all" onclick="toggleAllTables()">Collapse All Tables</button>
<button id="copyAllPlainBtn" class="copy-btn" type="button" onclick="copyAllTablesPlain()" aria-label="Copy all tables as plain text">Copy All Tables (Plain Text)</button>
<button id="copyAllTablesBtn" class="copy-all-btn" type="button" onclick="copyAllTablesMarkdown()" aria-label="Copy All Tables (Markdown)">Copy All Tables (Markdown)</button>
<button id="copyAllMdBtn" style="display:none" aria-hidden="true"></button>
<button id="resetAllBtn" type="button" onclick="resetAllTables()" aria-label="Reset All Tables">Reset All Tables</button>
</div></div>
<script>
(function(){
  function ensureDelegation(){
    try {
      var vis = document.getElementById('copyAllTablesBtn');
      var alias = document.getElementById('copyAllMdBtn');
      if(!vis || !alias) return;
      alias.addEventListener = function(type, listener, options){
        vis.addEventListener(type, listener, options);
      };
      alias.removeEventListener = function(type, listener, options){
        vis.removeEventListener(type, listener, options);
      };
      Object.defineProperty(alias, 'onclick', {
        set: function(fn){ vis.onclick = fn; },
        get: function(){ return vis.onclick; },
        configurable: true
      });
      alias.focus = function(){ vis.focus(); };
      alias.blur = function(){ vis.blur(); };
    } catch(e) {
      try{ console && console.warn && console.warn('alias delegation failed', e); }catch(_){} 
    }
  }
  if(document.readyState === 'loading'){
    document.addEventListener('DOMContentLoaded', ensureDelegation);
  } else {
    ensureDelegation();
  }
})();
</script>
<noscript><div style='color:#b91c1c'>JavaScript is disabled. Tables will be shown statically. For large tables enable JS for virtualization.</div></noscript>
<div id="tocBar" role="navigation" aria-label="Table of contents"><ul><li class="toc-item"><a class="toc-link" href="#Table1">Table 1</a></li>
<li class="toc-item"><a class="toc-link" href="#Table2">Table 2</a></li>
<li class="toc-item"><a class="toc-link" href="#Table3">Table 3</a></li>
<li class="toc-item"><a class="toc-link" href="#Table4">Table 4</a></li>
<li class="toc-item"><a class="toc-link" href="#Table5">Table 5</a></li>
<li class="toc-item"><a class="toc-link" href="#Table6">Table 6</a></li>
<li class="toc-item"><a class="toc-link" href="#Table7">Table 7</a></li>
<li class="toc-item"><a class="toc-link" href="#Table8">Table 8</a></li>
<li class="toc-item"><a class="toc-link" href="#Table9">Table 9</a></li>
<li class="toc-item"><a class="toc-link" href="#Table10">Table 10</a></li></ul></div></div>
<div class="table-caption" id="Table1" data-table="YJKN_0010_01" style="margin-top:2mm;margin-left:3mm;"><strong>Table 1</strong></div>
<div class="table-wrapper" data-table-id="table-1"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Learning outcomes — success definitions & funder-aligned indicators (inputs → impact)</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Primary learning outcomes (what learners will be able to do):</strong> <br> 1) Define success for a research project at each stage: Input, Activity, Output, Outcome, Impact. <br> 2) Design 3–5 measurable indicators for each stage aligned to funder expectations (UKRI/NIHR/Wellcome/REF styles). <br> 3) Produce a short monitoring plan (indicator, data source, frequency, owner) that satisfies common UK funder requirements (data management, open access, EDI, value-for-money). <br> 4) Critically appraise whether a proposed indicator is feasible, proportional and robust (avoids perverse incentives). </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Stage definitions (one-line each)</strong> <br> <strong>Input:</strong> resources mobilised to enable work (funds, staff, equipment, data access, approvals). <br> <strong>Activity:</strong> the work you do (fieldwork, lab experiments, analysis, workshops, training). <br> <strong>Output:</strong> direct, tangible products of activities (papers, datasets, protocols, policy briefs, software). <br> <strong>Outcome:</strong> short–medium term changes in use, behaviour, policy, capability (adoption by services, uptake in guidelines, trained staff applying skills). <br> <strong>Impact:</strong> longer-term, sustained change in society, economy, health, environment or systems attributable (reduced disease burden, changed policy, economic benefit). </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Success indicators — illustrative examples by stage (measurable & funder-friendly)</strong> <br> <strong>Inputs (examples):</strong> Budget variance ≤10%; named staff in post by project month 1; secure data access agreement signed before analysis. <br> <strong>Activities (examples):</strong> # participants recruited per month; % protocol adherence across sites; number of co-design workshops delivered. <br> <strong>Outputs (examples):</strong> peer-reviewed articles (OA) published; dataset with DOI deposited; policy brief disseminated to X stakeholders. <br> <strong>Outcomes (examples):</strong> # clinical sites adopting protocol within 12 months; % increase in practitioner knowledge (pre/post); citation of report in a governmental review. <br> <strong>Impact (examples):</strong> change in service metrics (e.g., 12% reduction in waiting time within 36 months), documented cost-savings to health system, contribution to a statutory guideline. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Indicator design rules (simple checklist)</strong> <br> - <strong>S</strong>pecific: clearly states what is measured. <br> - <strong>M</strong>easurable: has a numeric or binary metric. <br> - <strong>A</strong>chievable: realistic given resources & timeline. <br> - <strong>R</strong>elevant: links to project theory of change and funder priorities. <br> - <strong>T</strong>imebound: defined measurement period. <br> - <strong>Proportionality:</strong> avoid heavy reporting burden on small partners. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>How UK funders typically frame success (what to reflect in indicators)</strong> <br> - <strong>Pathways to impact / planning for impact:</strong> include who will use outputs and how (policy makers, clinicians, industry). (Include a short "pathway" narrative with each outcome indicator.) <br> - <strong>Open research & data management:</strong> outputs must plan for open access and data stewardship (DOI, repository, DMP). <br> - <strong>Research integrity & ethics:</strong> demonstrable approvals, safeguarding & ethical compliance. <br> - <strong>Value-for-money & feasibility:</strong> realistic budgets, staged spending, milestones linked to tranches. <br> - <strong>Equality, diversity & inclusion (EDI):</strong> EDI actions and monitoring where relevant (e.g., representative recruitment targets, authorship fairness). </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Typical evidence types funders expect (mapped to stage)</strong> <br> - <strong>Inputs:</strong> signed contracts, CVs, budget spreadsheets, DSA/agreements. <br> - <strong>Activities:</strong> attendance lists, lab logs, protocols, training records. <br> - <strong>Outputs:</strong> DOIs, publication links, software repo links, downloadable reports. <br> - <strong>Outcomes:</strong> uptake letters, policy citations, monitoring dashboards, pre/post evaluation data. <br> - <strong>Impact:</strong> independent evaluations, routine administrative data showing system change, economic appraisal. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Monitoring plan template (copy-ready columns)</strong> <br> <code>Indicator | Stage | Definition | Target | Data source | Frequency | Owner | Evidence link</code> <br> <em>Example row:</em> <code>Dataset deposited (DOI) | Output | Dataset with metadata &amp; DOI | 1 by month 12 | Repository receipt | Once at deposit | Data lead | [link]</code> </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Selecting indicators for UK funder expectations — practical rules</strong> <br> 1) Start with funder guidance: map funder priorities (impact, open access, ethics) to your outcomes. <br>2) Choose 1–2 primary indicators per stage and 1–2 risk/process indicators. <br>3) Use qualitative evidence for outcomes/impact as well as quantitative. <br>4) Pre-register data sources and ownership to avoid surprise audits. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Common KPIs funders ask for (short list to include where relevant)</strong> <br> - Number of outputs (OA papers / datasets with DOIs). <br> - Engagement events with named policy/practice stakeholders. <br> - Documented adopters (organisations/sites) of an intervention within X months. <br> - Demonstrable capacity built (e.g., number trained + evidence of application). <br> - Data management compliance (DMP approved, data deposited). <br> - Ethical approvals in place and safeguarding training completed. <br> - Value-for-money indicators: spend vs planned milestone, % budget on local partners (for equitable partnerships). </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Measurement methods & frequency — pragmatic guidance</strong> <br> - <strong>Activity monitoring:</strong> weekly or monthly trackers for recruitment, lab runs, workshop attendance. <br> - <strong>Output verification:</strong> repository checks at publication; automated DOI capture. <br> - <strong>Outcome assessment:</strong> short surveys, stakeholder interviews at 6–12 months post-output; routine data linkage where possible. <br> - <strong>Impact assessment:</strong> commissioning an external evaluation between 24–48 months where feasible, and using administrative datasets for long-term metrics. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>How to write indicators that survive review (language examples)</strong> <br> - Weak: "Improve practice." <br> - Strong: "Increase the proportion of participating clinics implementing protocol X from 0% to 40% within 12 months (measured by monthly implementation checklist)." <br> - Weak: "Engage policymakers." <br> - Strong: "Hold 3 bilateral briefings with named decision-makers in Department Y and obtain written feedback or agreed next steps." </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Risk & process indicators to include (funders expect governance flags)</strong> <br> - Ethics approval obtained by [date]. <br> - Data-sharing agreement signed before any data extraction. <br> - % of local partner invoices paid within agreed terms. <br> - % milestone deliverables on time. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Equity & EDI indicators (sample, funder-relevant)</strong> <br> - Proportion of project budget allocated to local partners (%) and admin support lines. <br> - Gender/age/ethnic representation targets in study recruitment or advisory boards where relevant. <br> - Number of junior researchers from partner institutions with named authorship roles or training. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Mapping indicators to typical funder reporting cycles (practical)</strong> <br> - <strong>Quarterly reports:</strong> activity & process KPIs, finance snapshot, immediate risks. <br> - <strong>Mid-term report (6–12 months):</strong> outputs produced, preliminary outcomes, corrective actions. <br> - <strong>Final report:</strong> outputs, outcomes achieved, evidence of impact pathways, lessons learned. <br> - <strong>Longer-term impact reporting (where required):</strong> follow-up evidence (REF/NIHR/UKRI impact statements or equivalent). </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Worked example (short: applied to a health intervention trial)</strong> <br> - <strong>Inputs:</strong> staff recruited (3/3 by month 1). KPI: staff in post = 3 (target met). <br> - <strong>Activities:</strong> 12 site training workshops delivered (KPI: 12 workshops; attendance lists). <br> - <strong>Outputs:</strong> protocol paper published OA (KPI: DOI by month 10); dataset deposited (KPI: DOI). <br> - <strong>Outcomes:</strong> 6 clinics adopt intervention within 12 months (KPI: documented adoption letters). <br> - <strong>Impact:</strong> reduction in readmission rate by X% at 36 months (KPI: routine data comparison adjusted for confounders). </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Evidence quality & triangulation — funder expectations</strong> <br> - Combine routine administrative data, independent evaluation, stakeholder testimony and documented outputs to make a persuasive evidence bundle. <br> - Avoid single-point claims (e.g., one testimonial) — triangulate with data or documentary evidence. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Short plan to operationalise these learning outcomes in a training session</strong> <br> 1) 20-min micro-lecture: stage definitions + funder priorities. 2) 30-min exercise: small groups draft 2 indicators for a provided project brief. 3) 20-min peer critique: check feasibility/proportionality. 4) 20-min plenary: map indicators to reporting cycle. 5) Provide a downloadable monitoring-plan template. </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Quick checks before you finalise indicators for a funder application</strong> <br> - Are indicators linked to the project's theory of change? (Yes/No) <br> - Are data sources realistic and owned? (Yes/No) <br> - Is reporting burden reasonable for partners? (Yes/No) <br> - Do indicators reflect funder priorities (impact, open access, EDI)? (Yes/No) <br> - Are owners and timelines assigned? (Yes/No) </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>Short reading & resources to consult (starter list)</strong> <br> - UKRI evaluation and impact guidance for planning and evaluation. <br> - NIHR materials on assessing impact plans and responsible metrics. <br> - Wellcome guidance on research assessment, open research and research integrity. <br> - REF guidance on engagement and impact (where outputs underpin institutional assessments). </td></tr><tr><td data-label="Learning outcomes — success definitions &amp; funder-aligned indicators (inputs → impact)"> <strong>One-line aide-memo for learners:</strong> <br> "Define success at each stage, pick a small number of measurable indicators tied to the pathway-to-impact, make evidence sources explicit, and protect partner capacity by keeping monitoring proportionate." </td></tr></tbody></table></div><div class="row-count">Rows: 20</div></div><div class="table-caption" id="Table2" data-table="YJKN_0010_02" style="margin-top:2mm;margin-left:3mm;"><strong>Table 2</strong></div>
<div class="table-wrapper" data-table-id="table-2"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Logic model — Pharmacological assessment project (idea → impact)**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Logic model — Pharmacological assessment project (idea → impact)</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Context & one-line stage definitions</strong> <br> <strong>Input:</strong> resources mobilised to enable work (funds, staff, equipment, data access, approvals). <br> <strong>Activity:</strong> the work you do (fieldwork, lab experiments, analysis, workshops, training). <br> <strong>Output:</strong> direct, tangible products of activities (papers, datasets, protocols, policy briefs, software). <br> <strong>Outcome:</strong> short–medium term changes in use, behaviour, policy, capability (adoption by services, uptake in guidelines, trained staff applying skills). <br> <strong>Impact:</strong> longer-term, sustained change in society, economy, health, environment or systems attributable (reduced disease burden, changed policy, economic benefit). </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Project summary (one line):</strong> Assess the safety, effectiveness and real-world use of a pharmacological intervention and produce evidence and tools for safer, more effective prescribing and policy adoption. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Inputs (examples tailored to pharmacology)</strong> <br> - Funding (phases: pilot, pivotal, dissemination). <br> - Human resources: clinical pharmacologists, pharmacovigilance specialists, clinicians, biostatisticians, data engineers, trial coordinators, regulatory/legal advisor, community liaison. <br> - Infrastructure: clinical sites, labs (bioanalysis/PK), cold chain, secure data environment, EHR access agreements. <br> - Approvals & governance: ethics committee, national drug regulator (if needed), data-sharing agreements, indemnity. <br> - Materials: investigational product (if interventional), comparator drugs, assay kits, consumables. <br> - Partnerships: hospitals, primary-care networks, public health agencies, patient groups. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Key activities (typical workstreams)</strong> <br> - Protocol & SOP development (clinical, lab, data). <br> - Regulatory & ethics submissions and approvals. <br> - Site selection & training (GCP, safety reporting). <br> - Data access setup (EHR extract, linkage, pseudonymisation). <br> - Laboratory assays (PK/PD, biomarker validation). <br> - Clinical data collection or trial conduct (observational cohorts, RCT or pragmatic trials). <br> - Pharmacovigilance & safety monitoring (AE reporting, DSMB reviews). <br> - Statistical analysis (pre-specified analysis plan, population definitions). <br> - Stakeholder engagement & co-design (clinicians, guideline bodies, patients). <br> - Dissemination & implementation planning (policy briefs, training). </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Immediate outputs (tangible deliverables)</strong> <br> - Study protocol, SOPs, data management plan. <br> - Cleaned, documented dataset(s) and code (repo + DOI). <br> - PK/PD assay validation reports and lab SOPs. <br> - Safety reports and DSMB minutes. <br> - Statistical analysis report and preprint / peer-reviewed article(s). <br> - Policy brief, clinical guidance draft, and clinician training materials. <br> - Data-sharing package and regulatory submission dossiers (if required). </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Short–medium outcomes (use & adoption)</strong> <br> - Clinician uptake: guideline or formulary adoption in pilot regions. <br> - Practice change: measurable change in prescribing patterns or dosing. <br> - Improved clinical pathways: reduced inappropriate use or better monitoring. <br> - Capability: trained local staff performing PK assays or safety monitoring. <br> - Policy traction: regulator or payer engages with evidence for label/coverage change. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Impact (longer-term, measurable change)</strong> <br> - Reduced adverse drug reactions and hospital admissions attributable to medication. <br> - Improved patient outcomes (disease-specific metrics). <br> - Cost-savings for health services via optimized prescribing. <br> - Sustained integration of monitoring in routine care and updated national guidance. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Indicators & example metrics (mapped to model levels)</strong> <br> <strong>Inputs:</strong> funding disbursed vs plan (%), staff FTE onboarded, number of site agreements signed. <br> <strong>Activities:</strong> % sites activated, % protocol adherence, number of samples processed/month. <br> <strong>Outputs:</strong> datasets published (count), code repo with DOI (yes/no), number of peer-reviewed articles, number of policy brief downloads. <br> <strong>Short outcomes:</strong> % clinicians adopting guidance in pilot region, change in prescribing rate (%) within 6 months, number trained applying new protocol. <br> <strong>Impact:</strong> change in ADE-related hospitalisations per 1000 patients over 24 months; QALYs or DALYs averted if applicable; budget impact for health service. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Assumptions (what must hold true)</strong> <br> - Data access agreements and high-quality data are available. <br> - Regulatory and ethics approvals are granted without major changes to protocol. <br> - Clinical sites have capacity and staff willingness to collect required data. <br> - Stakeholders (clinicians, policymakers) will engage with co-design and implementation. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Risks & mitigations (practical examples)</strong> <br> <strong>Risk:</strong> delayed regulatory/ethics approvals → <strong>Mitigation:</strong> parallel submission prep, conservative timelines, early regulator engagement. <br> <strong>Risk:</strong> data linkage impossible or poor quality → <strong>Mitigation:</strong> plan alternate data sources, sample-based validation, stepwise analysis plan. <br> <strong>Risk:</strong> safety signal requiring pause → <strong>Mitigation:</strong> DSMB charter, pre-defined stopping rules, rapid communication plan and contingency budget for additional investigations. <br> <strong>Risk:</strong> low recruitment/participation → <strong>Mitigation:</strong> broaden inclusion sites, community engagement, small incentives, adaptive design. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Decision points & go/no-go criteria (operational triggers)</strong> <br> - <strong>Go to pilot:</strong> protocol finalised, ethics/regulatory positive opinion, at least X sites activated, data pipeline tested end-to-end. <br> - <strong>Interim safety review:</strong> pre-specified thresholds for SAE rates; if exceeded, pause and investigate. <br> - <strong>Analysis decision:</strong> pre-specified effect size and confidence interval thresholds for moving from pilot to scale; if not met, trigger redesign or targeted implementation. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Evaluation & attribution strategy</strong> <br> - Use mixed methods: quantitative (pre/post prescribing, interrupted time series, cohort comparisons) + qualitative (clinician interviews, implementation case studies). <br> - For causal claims, use design-appropriate approaches (RCT or quasi-experimental methods) and document contribution pathways when attribution is partial. <br> - Pre-register analysis plan and publish protocols to reduce bias. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Roles & responsibilities (recommended assignments)</strong> <br> - PI / Clinical Lead: strategy, regulator liaison, ultimate decisions. <br> - Project Manager: schedule, budget, coordination, records. <br> - Data Lead: data pipeline, linkage, environment. <br> - Lab Lead: assay validation, sample logistics. <br> - Safety Officer / DSMB Secretary: AE reporting, safety monitoring. <br> - Implementation Lead: stakeholder engagement, training, guideline drafting. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Timeline example (high-level phases)</strong> <br> - Months 0–3: set-up — protocol, approvals, site agreements, data environment. <br> - Months 3–9: pilot data collection, assay validation, interim safety checks. <br> - Months 9–15: analysis, stakeholder co-design of guidance. <br> - Months 15–24: dissemination, implementation pilot, evaluation of uptake. <br> - Months 24+: scale-up & impact monitoring. (Adapt to project scale and regulatory timelines.) </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Budget priorities (must-lines for pharmacological work)</strong> <br> - Regulatory & ethics costs; secure data environment fees; lab assays & consumables; personnel (site coordinators, lab technicians, statisticians); site reimbursements and local admin; travel/meetings for stakeholder co-design; contingency for safety investigations. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Implementation supports (to turn outputs into outcomes)</strong> <br> - Clinician training modules and quick reference dosing cards. <br> - Decision support integrated into EHR (order sets, alerts). <br> - Policy briefings with economic modelling for payers. <br> - Local pilot champions and mentorship for sites adopting new protocols. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Monitoring dashboard suggestions (minimum fields)</strong> <br> - Project status (Red/Amber/Green), sites activated, samples processed, AEs reported (by severity), actions overdue, budget burn vs plan, next decision milestone. Update cadence weekly for ops, monthly for leadership. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Quick checklist for proposal text (copy-ready bullets)</strong> <br> - Objective: measure safety and real-world effectiveness of [drug/intervention] and produce implementable guidance. <br> - Primary indicators: SAE rate per 1000 patient-months; change in prescribing appropriateness (%) at 12 months. <br> - Key governance: DSMB, ethics approvals, data sharing MOU. <br> - Dissemination: peer-reviewed paper, policy brief, EHR decision support package, clinician workshops. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>Common pitfalls specific to pharmacological projects</strong> <br> - Underestimating regulatory timelines for drug-related work. <br> - Poorly specified safety monitoring leading to slow responses. <br> - Data heterogeneity across sites undermining pooled analysis—plan harmonisation up-front. <br> - Overlooking supply/logistics for investigational product or comparator. </td></tr><tr><td data-label="Logic model — Pharmacological assessment project (idea → impact)"> <strong>One-line summary (project success criterion):</strong> Demonstrable, clinician-adopted, evidence-based change in prescribing or monitoring—supported by robust safety data and sustainable implementation pathways—leading to measurable patient benefit. </td></tr></tbody></table></div><div class="row-count">Rows: 20</div></div><div class="table-caption" id="Table3" data-table="YJKN_0010_03" style="margin-top:2mm;margin-left:3mm;"><strong>Table 3</strong></div>
<div class="table-wrapper" data-table-id="table-3"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Outcomes & Impacts — pharmacological assessment project (focused operational guide)</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Purpose & scope</strong> <br> Focus this section of the logic model on the measurable short, medium and long outcomes and the pathways to impact for a pharmacological assessment project. Provide indicators, evaluation designs, attribution approaches, equity lenses, risk mitigation and operational triggers that convert outputs (datasets, reports, guidance) into sustained improvements in prescribing, safety monitoring and patient outcomes. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Outcome definitions (one-line each)</strong> <br> <strong>Short outcomes (0–12 months):</strong> immediate changes in knowledge, availability of tools and early adoption signals (e.g., training completed; decision-support installed). <br> <strong>Medium outcomes (6–24 months):</strong> measurable changes in practice, policy or capability (e.g., prescribing patterns change, regulator engages, piloted guidelines adopted locally). <br> <strong>Long outcomes / impact (24+ months):</strong> sustained population-level or system-level changes (e.g., reduced ADE hospitalisations, cost-savings, guideline incorporation nationally). </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Outcome pathway summary (chain of change)</strong> <br> Outputs (validated dataset, assay, guidance, training) → Implementation supports (EHR integration, training, champions) → Short outcomes (awareness, tools available, initial adoption) → Medium outcomes (practice change, policy adoption, monitored uptake) → Impact (health outcomes, economic benefits, system resilience). Each link needs indicators, owners, and evidence. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Key short outcomes — what to measure and why</strong> <br> 1) <strong>Tool availability:</strong> Decision-support tool deployed in X pilot clinics — Indicator: deployment count (target X). <br> 2) <strong>Training delivered:</strong> #clinicians trained and % passing competency check — Indicator: trainee count & competency pass rate. <br> 3) <strong>Access to evidence:</strong> policy brief downloads, repo DOI hits — Indicator: downloads / repo clones. <br> 4) <strong>Safety surveillance active:</strong> pharmacovigilance reporting channel live — Indicator: reports submitted per month. <br> <strong>Why:</strong> short outcomes signal readiness and capacity to act on outputs. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Key medium outcomes — what to measure and why</strong> <br> 1) <strong>Prescribing change:</strong> % reduction in inappropriate prescriptions or adjusted dosing rate — Indicator: prescribing rate change vs baseline. <br> 2) <strong>Guideline uptake:</strong> number of institutions adopting new protocol or formulary change — Indicator: adoption count & coverage. <br> 3) <strong>Improved monitoring:</strong> % patients receiving recommended monitoring (labs, PK sampling) — Indicator: monitoring compliance. <br> 4) <strong>Regulatory action/stance:</strong> regulator issues guidance or label change — Indicator: engagement milestone or formal communication. <br> <strong>Why:</strong> medium outcomes show behaviour and policy change required for impact. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Impact outcomes — measurable long-term change</strong> <br> 1) <strong>Clinical outcomes:</strong> reduction in ADE-related admissions per 1,000 patients over 24 months. <br> 2) <strong>Health gain:</strong> QALYs gained or DALYs averted (if estimable). <br> 3) <strong>Economic outcomes:</strong> net cost-savings to payer (drug + hospital costs) or cost per QALY. <br> 4) <strong>System resilience:</strong> routine pharmacovigilance sustained and integrated into national surveillance. <br> <strong>Why:</strong> impact demonstrates value and justifies scale and policy changes. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Indicator design — principles</strong> <br> - SMART: Specific, Measurable, Achievable, Relevant, Time-bound. <br> - Feasible: data source exists or is collectable without excessive burden. <br> - Balanced: include process, output, outcome and impact indicators. <br> - Equity-disaggregated: by age, sex, geography, socio-economic status to detect unequal effects. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Example indicator matrix (short → impact)</strong> <br> - Short: Clinician training count → Source: training registers. <br> - Short: Decision-support installed (n clinics) → Source: IT logs. <br> - Medium: % appropriate prescriptions (6 months) → Source: EHR extracts. <br> - Medium: Guideline adoption (policy memo) → Source: institutional records. <br> - Impact: ADE admission rate per 1,000 (24 months) → Source: hospital admin data. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Data sources & quality notes</strong> <br> - EHR / prescribing databases: primary source for prescribing, monitoring and outcomes. Validate coding and denominators. <br> - Hospital administrative data: ADE admissions, length-of-stay. Check ICD/diagnosis mapping. <br> - Pharmacovigilance reports: SAE counts; may under-report — use triangulation. <br> - Training databases & surveys: measure self-reported behaviour change but triangulate with prescribing data. <br> - Economic data: unit costs, drug prices, hospital costing templates required for budget impact modelling. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Measurement methods & evaluation designs</strong> <br> - <strong>Randomised designs (gold standard):</strong> cluster RCT if interventions can be randomised (e.g., messaging, decision-support). Outcomes: prescribing rates, ADEs. Use intention-to-treat analysis. <br> - <strong>Quasi-experimental:</strong> stepped-wedge, interrupted time series (ITS) for phased rollout; appropriate when randomisation infeasible. <br> - <strong>Observational:</strong> cohort or case-control with careful confounder control (propensity scores). <br> - <strong>Mixed-methods:</strong> qualitative process evaluation to explain adoption, barriers and fidelity. <br> - <strong>Economic evaluation:</strong> trial-based cost-effectiveness or modelled cost-utility (QALY). </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Attribution & contribution strategies</strong> <br> - For outputs → short outcomes: direct linkage plausible; use usage logs and immediate pre/post comparisons. <br> - For medium outcomes: use ITS or controlled before-after designs where possible; document alternative explanations. <br> - For impact: build a contribution narrative supported by quantitative estimates, sensitivity analysis, and stakeholder testimony; include counterfactuals where feasible. <br> - Always pre-register analysis plan and assumptions. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Equity & distributional outcomes</strong> <br> - Measure differential uptake and impact by geography, income, gender, ethnicity/indigeneity, and facility type. <br> - Indicators: adoption rates per subgroup, change in prescribing inequities, access to monitoring. <br> - Include targeted mitigation (subsidies, training, connectivity) when early signals show unequal uptake. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Unintended consequences to monitor</strong> <br> - Risk of switching harms (replacing one drug with another causing other ADEs). <br> - Alert fatigue from decision-support leading to override behaviour. <br> - Inequitable access (richer hospitals adopt faster). <br> - Perverse prescribing behaviour to meet metrics. <br> <strong>Mitigation:</strong> monitor for signal patterns, iterative design, clinician feedback loops, adjust thresholds. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Fidelity & process outcomes</strong> <br> - Fidelity metrics: % adherence to protocol, % sites implementing SOPs fully. <br> - Dose-delivered vs dose-received for training. <br> - Contextual process measures: staffing levels, supply stability, IT uptime. <br> <strong>Why:</strong> poor fidelity explains lack of outcome even when outputs exist. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Economic & budget impact outcomes</strong> <br> - Short-term costs incurred: implementation, training, IT integration. <br> - Medium-term budget impact: drug cost changes, monitoring costs, potential savings from avoided ADEs. <br> - Impact-level: net budget impact and cost-effectiveness (cost per QALY). <br> <strong>Metrics:</strong> incremental cost-effectiveness ratio (ICER), net monetary benefit, payback period. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Policy & governance outcomes</strong> <br> - Evidence uptake by guideline committees: number of meetings engaging evidence, official citations in guidance. <br> - Procurement/formulary decisions indicating coverage. <br> - Embedding monitoring responsibilities into institutional SOPs. <br> <strong>Indicators:</strong> date of guideline update, wording changes referencing project outputs, budget allocation lines created. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Capacity-building outcomes</strong> <br> - Number of staff certified in PK/PD assays or safety monitoring. <br> - Local lab capability sustained post-project (assay runs/month). <br> - Knowledge transfer measured via co-authored outputs or new local protocols. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Behavior change & clinician adoption outcomes</strong> <br> - Adoption curve: early adopters → majority → laggards tracked via monthly prescribing data. <br> - Clinician behaviour indicators: proportion of clinicians following new dosing, percentage using decision-support. <br> - Sustainment: adherence measured at 6, 12, 24 months post-intervention. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Patient-level outcomes & experience</strong> <br> - Clinical endpoints: symptom control metrics, adverse event rates, readmissions. <br> - Patient-reported outcomes: satisfaction, adherence, side-effect burden. <br> - Equity lens: differential patient outcomes by subgroup. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Scaling & sustainability outcomes</strong> <br> - Demonstrated feasibility of handover to local systems (technical, financial). <br> - Funding or budget lines secured for ongoing monitoring. <br> - Institutional champions and maintenance plans in place. <br> <strong>Indicators:</strong> handover plan signed, budget lines allocated, helpdesk/support arrangement active. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Decision triggers & operational thresholds (examples)</strong> <br> - <strong>Continue to scale:</strong> pilot effect size ≥ pre-specified threshold AND safety signal absent. <br> - <strong>Pause:</strong> SAE rate exceeds threshold or data integrity fails. <br> - <strong>Redesign:</strong> adoption below threshold and fidelity < 60% with identifiable causes. <br> - <strong>Stop:</strong> irreconcilable ethical/regulatory barrier or sustained net harm. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Reporting cadence & audiences</strong> <br> - Operational dashboard: weekly ops for sites (SAEs, recruitment, actions). <br> - Leadership report: monthly RAG summary + key risks. <br> - Policy briefs: staged at analysis completion and pre-scale. <br> - Public outputs: peer-reviewed publication and open datasets on archive (with DOI). </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Evaluation plan — minimum components</strong> <br> - Pre-specified primary and secondary outcome measures with analysis methods. <br> - Data management plan and provenance for each indicator. <br> - Power/sample calculations for main outcomes (if inferential). <br> - Mixed-methods process evaluation to explain outcomes. <br> - Economic evaluation plan. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Sample evaluation timeline (focus on outcomes)</strong> <br> - Baseline data extraction: month -1 to 0. <br> - Short outcome measurement: months 3, 6, 12 (training uptake, tool usage). <br> - Medium outcome measurement: 6–18 months (prescribing changes, guideline adoption). <br> - Impact measurement: 24+ months (ADE admissions, cost-savings). </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Causal inference checklist (to support attribution)</strong> <br> - Clear pre/post timelines and intervention start date. <br> - Control or comparison sites where feasible. <br> - Adjustment for secular trends and seasonality (ITS). <br> - Sensitivity analyses (different model specifications). <br> - Triangulation with qualitative evidence. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Stakeholder & communication outcomes</strong> <br> - Stakeholder engagement: number & diversity of stakeholders consulted, signed MOUs. <br> - Communication efficacy: policy brief distribution metrics and targeted meetings completed. <br> - Media & public engagement metrics where relevant (reach, sentiment). </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Ethics & safety outcome reporting</strong> <br> - Timeliness of SAE reporting (median reporting lag). <br> - Number of safety-related protocol amendments and reasons. <br> - Evidence of enacted mitigations from DSMB recommendations. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Equity & harm-minimisation outcomes</strong> <br> - Monitoring for differential harms by subgroup and rapid mitigation plans (e.g., targeted outreach, subsidy for monitoring costs). <br> - Outcome: reduction in inequity gap in prescribing or ADEs over time. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Data governance & privacy outcomes</strong> <br> - Number of successful secure analyses completed in approved environment. <br> - Breach incidence (target zero) and response time. <br> - Data sharing agreements executed and tracked. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Practical KPIs (dashboard-ready)</strong> <br> - % clinicians trained (target X%). <br> - % sites with decision-support active (target X%). <br> - % appropriate prescribing change (target % reduction). <br> - SAE rate per 1,000 (target threshold). <br> - Time to policy engagement (days from analysis to meeting). </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Templates for outcome targets (copy-ready)</strong> <br> - "By month 12, increase appropriate prescribing rate in pilot hospitals by 20% (baseline X% → target Y%)." <br> - "By month 18, at least 3 regional guideline committees will have received and considered the evidence; one will formally adopt wording into local guidance." </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Risk-adjusted interpretation of outcomes</strong> <br> - Always contextualise outcome changes by fidelity, supply constraints and external shocks (e.g., drug shortages). <br> - Use adjusted models and report both crude and adjusted estimates. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Rapid feedback & iterative improvement loop</strong> <br> - Use monthly outcome reviews to identify low-adoption sites and deploy targeted remedial actions (training, IT fixes). <br> - Document change cycles and measure post-intervention effects to show improvement over time. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Cost-effectiveness & budget-impact outputs to support impact claims</strong> <br> - Present ICERs, net budget impact and scenario analyses (best, base, worst). <br> - Use local costing data and sensitivity analysis for generalisability. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Policy translation & impact evidence package</strong> <br> - Combine: executive summary, short evidence brief, economic model, implementation guide, slide deck, and local pilot case study. <br> - Include clear ask for policymakers (e.g., "adopt guideline X in these settings and allocate Y funding"). </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Sustainability indicators (handover success)</strong> <br> - % of pilot sites with allocated maintenance budget 12 months post-project. <br> - % of trained staff still performing tasks at 12 months. <br> - Local ownership: number of local-led adaptations and publications. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Final checklist — outcomes to demonstrate project success</strong> <br> - Short outcomes: tools deployed, staff trained, surveillance active. <br> - Medium outcomes: measurable prescribing change, guideline adoption, regulator engagement. <br> - Impact: reduced ADE admissions, improved patient outcomes, cost-savings. <br> - All layers: include equity metrics, fidelity assessment, and documented causal narrative. </td></tr><tr><td data-label="Outcomes &amp; Impacts — pharmacological assessment project (focused operational guide)"> <strong>Offer:</strong> if useful I can convert this into a one-page outcomes dashboard template or a populated outcomes table with sample targets for your specific drug/intervention and settings. </td></tr></tbody></table></div><div class="row-count">Rows: 38</div></div><div class="table-caption" id="Table4" data-table="YJKN_0010_04" style="margin-top:2mm;margin-left:3mm;"><strong>Table 4</strong></div>
<div class="table-wrapper" data-table-id="table-4"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Why a contract is needed — improved operational guide (organized by your outline)**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Why a contract is needed — improved operational guide (organized by your outline)</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Purpose (short):</strong> A contract turns mutual expectations into enforceable, auditable commitments so teams can act with clarity, protect assets, manage risk, and sustain collaboration. Contracts are governance tools for decisions, money, data, IP and reputation. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Core reasons mapped to your outline</strong> <br> <strong>Clarity & responsibilities:</strong> precisely states who does what, deliverable definitions, acceptance criteria, owners and deadlines so operational ambiguity is eliminated. <br> <strong>Protect intellectual property:</strong> defines foreground/background IP, ownership, licensing, commercialisation rights, moral rights and review/embargo windows for manuscripts. <br> <strong>Ensure legal & compliance:</strong> sets governing law, authorised signatories, sanctions/PEP checks, export controls, ethics/IRB obligations and compliance reporting. <br> <strong>Manage risk & liability:</strong> allocates financial and operational risk, liability caps, indemnities, insurance requirements, and termination triggers. <br> <strong>Control data usage:</strong> specifies data access, permitted uses, secure environments, retention/deletion, audit logs, breach notification and cross-border rules. <br> <strong>Enable collaboration:</strong> specifies decision-making bodies, authorship rules, dispute resolution, steering/management structures, and resource-sharing rules. <br> <strong>Sustainability & stewardship:</strong> requires long-term stewardship (data, sample + code), archiving, maintenance responsibilities, and handover plans. <br> <strong>Protect institutional interests:</strong> confirms institutional sign-off, fund-flow routing, procurement rules, tax compliance and audit rights. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Anatomy of a good research/partnership contract (layered view)</strong> <br> <strong>Framework layer (governance & metadata):</strong> parties, authorised signatories, term, governing law, definitions, annex list, insurance summary, and high-level decision/governance map (steering group, PM, WP leads). <br> <strong>Scope & responsibilities (Statement of Work / SOW):</strong> clear deliverables, acceptance tests, milestones, outputs, owner per deliverable, timeline and budget lines. <br> <strong>Provisions (commercial & protective clauses):</strong> payment schedule, invoicing, audit rights, change control, termination, confidentiality, sanctions/compliance, force majeure, indemnities and insurance. <br> <strong>Publication & dissemination:</strong> authorship criteria, review windows, embargo periods, acknowledgement text, communications protocol and approval process for public statements. <br> <strong>Data & materials management:</strong> DSA/Annex: data types, access environment, permitted uses, anonymisation/pseudonymisation, retention, destruction, transfer, archiving repository, sample handling (if biological), and breach processes. <br> <strong>Risk management & controls:</strong> risk register references, remedial actions, milestone-linked holdbacks/escrow, performance remedies, and conditional payment triggers. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Concrete contract clauses & short explanations</strong> <br> <strong>Scope / acceptance:</strong> "Deliverable D accepted when [test], acceptance notice within 10 business days or deemed accepted." <br> <strong>Payment & control:</strong> "Payments: 30% on start, 40% on delivery, 30% on acceptance. Payments conditional on receipt of evidence and cleared audit." <br> <strong>IP & publications:</strong> "Foreground IP jointly owned / licensed as follows. Publication requires 30 days' review for confidential data and comments must be reasonable." <br> <strong>Data security:</strong> "Data processed in approved secure environment; access limited to named staff; exports require written permission; breach notified within 72 hours." <br> <strong>Liability & indemnity:</strong> "Liability capped at [amount], excluding wilful misconduct. Each party indemnifies for negligent acts and third-party claims arising from its breach." <br> <strong>Termination & suspension:</strong> "Material breach with 30-day cure; funder/PI may suspend payments pending remediation." </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Contract types — when to use each (short guidance)</strong> <br> <strong>Funding agreement (funder → recipient):</strong> use for grants; prescriptive reporting, audit, allowable costs, branding, and termination for funder non-compliance. <br> <strong>Collaboration agreement / consortium agreement:</strong> use when multiple partners co-design and co-own outputs; emphasises governance, IP sharing, authorship rules, decision procedures and dispute resolution. <br> <strong>Subaward / subcontract:</strong> use when passing funds or services through a prime; ensure flow-down of data, audit, IP and termination clauses; prime remains ultimately accountable to funder. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>How contracts achieve your eight objectives (practical checks)</strong> <br> <strong>Clarity & responsibilities:</strong> SOW + action owner table in Annex; acceptance tests. <br> <strong>Protect IP:</strong> foreground/background definitions, licences, commercialisation plan and revenue share. <br> <strong>Legal & compliance:</strong> clause requiring compliance with applicable laws, sanctions checks and required approvals (ethics, institutional). <br> <strong>Risk & liability:</strong> risk register annex + conditional payments/escrow + insurance levels named. <br> <strong>Control data usage:</strong> DSA with secure environment, access logs, audit rights and retention schedule. <br> <strong>Enable collaboration:</strong> governance schedule (steering/PM/WP), decision quorum and change control process. <br> <strong>Sustainability & stewardship:</strong> archiving repo, long-term budgets for maintenance, named steward and handover obligations. <br> <strong>Protect institutional:</strong> signatory verification, fund-flow map, procurement rules and tax/residency clauses. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Practical implementation pattern (copy-ready steps)</strong> <br> 1) Draft short SOW and risk summary before full contract drafting. <br> 2) Run fast due-diligence (registration, signatory, insurance). <br> 3) Agree governance & data steward names. <br> 4) Legal/finance/Data review with tracked redlines. <br> 5) Insert conditional controls (escrow, milestone holds). <br> 6) Sign & upload signed PDF to canonical archive; log IndexNo and link to action tracker. <br> 7) Monitor compliance: monthly milestone check + quarterly risk review. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Short templates (copy-ready snippets)</strong> <br> <strong>Acceptance test snippet:</strong> "Acceptance = completion of test A and submission of evidence B; acceptance notice due within 10 business days." <br> <strong>Data clause snippet:</strong> "Data shall only be used for the Project. Analysis must occur in the agreed SRE. No re-export without written consent." <br> <strong>Authorship snippet:</strong> "Authorship follows agreed contribution criteria (ICMJE or adapted); draft manuscripts circulated 30 days prior to submission for comment." </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Scaling diligence & contract complexity by risk/value</strong> <br> - <strong>Low risk / low value (<£10k):</strong> short SOW + payment terms; PI sign-off; minimal DSA if no sensitive data. <br> - <strong>Medium (£10k–£250k):</strong> standard SOW, legal & finance review, DSA for personal data, named insurers. <br> - <strong>High (>£250k) or sensitive:</strong> full legal negotiation, escrow options, comprehensive DSA, indemnities and senior sign-off. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Common negotiation trade-offs & guidance</strong> <br> - Keep acceptance criteria and payments linked — negotiable but non-negotiable as a principle. <br> - Liability caps can be negotiated (proportional to value); for clinical or high-risk work expect lower or no caps. <br> - Publication review windows should be short (e.g., 30 days) and limited to factual corrections or confidentiality concerns — avoid indefinite review rights. <br> - Flow-down key clauses to subs to avoid compliance gaps. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Operational checklist to use before signing (copy-ready)</strong> <br> - SOW clear with owners & acceptance tests? (Yes/No) <br> - Data types & DSA present and implementable? (Yes/No) <br> - IP ownership and publication rules agreed? (Yes/No) <br> - Liability & insurance adequate? (Yes/No) <br> - Authorised signatories and bank details validated? (Yes/No) <br> - Fund-flow & procurement rules compatible with partners? (Yes/No) <br> - Escalation and dispute route recorded? (Yes/No) </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Records & governance after signing</strong> <br> - Archive signed contract with IndexNo in <code>/03_Contracts</code>. <br> - Link contract to Action Tracker and Finance payment schedule. <br> - Log deviations as formal change orders with dates, owner and impact. <br> - Keep a renewal/expiry dashboard and insurance expiry alerts. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Fast conflict resolution clauses (practical):</strong> <br> - Step 1: good-faith negotiation (15 days). <br> - Step 2: mediation (30 days). <br> - Step 3: arbitration or jurisdictional court as last resort. <br> - Note: mediation/arbitration preserves relationships often better than immediate litigation. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>One-line aide-memo for busy teams:</strong> <br> "Get scope, payments, data rules and acceptance tests right first; use conditional payments and named stewards to manage risk and sustainability." </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Governance — approval requirements (operational guidance)</strong> </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Purpose:</strong> Define who may approve what, under what evidence and thresholds, how approvals are requested, recorded and audited. Clear approval rules reduce delays, prevent scope creep, enforce compliance and allocate accountability. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Key principles:</strong> <br> 1) <strong>Separation of duties:</strong> those who propose should not be sole approvers for high-risk items. <br> 2) <strong>Proportionality:</strong> approval depth matches risk/value. <br> 3) <strong>Delegation with limits:</strong> delegations must be written, time-bounded and published. <br> 4) <strong>Evidence-first:</strong> approvals require one-line ask + attachments (evidence). <br> 5) <strong>Traceability:</strong> every approval logged with <code>Who | What | When | Evidence | IndexNo</code>. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>What routinely requires approval (core list):</strong> <br> - Budget lines and reallocation above agreed thresholds. <br> - Contract or MOU signature and subaward issuance. <br> - Data sharing agreements and cross-border data transfers. <br> - Ethics approvals and protocol changes to approved ethics. <br> - Publication submissions (where funder/partner review required). <br> - Major scope changes (timeline, deliverables, geography). <br> - Procurement above defined amounts and vendor selection exceptions. <br> - Staff hires or changes to named personnel on grants. <br> - Use of restricted resources (facility access, special equipment). </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Approval hierarchy (example decision matrix)</strong> <br> <code>Value / Risk</code> → <code>Required Approver</code> <br> - <strong>Operational (<= £5k):</strong> WP Lead / PM (documented). <br> - <strong>Moderate (£5k–£50k):</strong> PI + Finance Reviewer. <br> - <strong>Significant (£50k–£250k):</strong> PI + Finance + Institutional Grants Office. <br> - <strong>Major (> £250k):</strong> Institutional signatory / Director + Legal + Funders (if required). <br> - <strong>Contracts / Data Sharing / IP:</strong> Legal + Data Custodian + Institutional signatory regardless of value. <br> - <strong>Ethics / Human subjects:</strong> Ethics Committee approval + PI sign-off before activity. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Delegation & authority rules:</strong> <br> - Delegations must be recorded in a <code>Delegation Register</code> (name, scope, limits, expiry, substitutable persons). <br> - Temporary delegation for emergencies must be documented in writing within 48 hours and ratified at next steering meeting. <br> - No delegation for legal signatory unless institutionally authorised. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Approval evidence & minimal package:</strong> <br> - <strong>One-line ask:</strong> action — owner — due. <br> - <strong>Rationale (1 paragraph):</strong> why decision now, options considered. <br> - <strong>Attachments:</strong> SOW or change note, budget impact table, risk assessment update, relevant approvals/ethics, sample contract redlines (if any). <br> - <strong>Recommendation:</strong> preferred option + fallback. <br> - <strong>Signature block:</strong> approver name, role, signature (digital ok), date. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Approval workflow (recommended steps):</strong> <br> 1) Proposer prepares Approval Pack and logs in Approval Tracker with IndexNo. <br> 2) Pre-brief (if high-impact) — 10–15 minute call with approver(s). <br> 3) Send formal approval request email with pack and 48–72h SLA (or shorter for urgent). <br> 4) Approver records decision in tracker and attaches signed approval. <br> 5) PM implements or escalates per decision; update action tracker. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Timing & SLAs:</strong> <br> - Routine operational approvals: 3–5 working days. <br> - Moderate: 5–10 working days. <br> - Major / contractual approvals: 10–20 working days (allow legal review). <br> - Emergency approvals: immediate pre-brief → documented retrospective approval within 48 hours and ratification at next steering meeting. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Record-keeping & audit trail:</strong> <br> - Store signed approvals in <code>/03_Contracts</code> or <code>/04_Approvals</code> with IndexNo. <br> - Approval log fields: <code>IndexNo | RequestDate | Proposer | Action | ValueImpact | Approver(s) | Decision | SignedDoc | Due/ImplementedDate | Notes</code>. <br> - Link approvals to finance disbursements and action tracker entries. <br> - Retain for funder/audit-required periods (per funder policy). </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Change control & versioning:</strong> <br> - Changes to scope require a <code>Change Request</code> form: original clause, proposed amendment, budget impact, risk delta, approver signature(s). <br> - Use versioned SOWs and maintain a <code>Change Log</code> (ID, date, author, approver, effect). <br> - Minor changes within delegation limits proceed with notification; material changes require formal approval. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Escalation rules & dispute resolution:</strong> <br> - If approver unavailable: escalate per Delegation Register or to next-level approver after 48h. <br> - If disagreement between approvers: convene quick steering call (48h); use PI as tie-breaker only if pre-agreed; unresolved matters go to institutional director/legal. <br> - For cross-institution disputes, follow consortium dispute clause (mediation → arbitration). </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Data & ethics approval specifics:</strong> <br> - No data transfer or human-subject activity without documented Ethics Committee clearance and signed DSA. <br> - Data access approvals must name users, environment (SRE), and retention period; any deviation needs Data Custodian + Legal approval. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Publication & dissemination approvals:</strong> <br> - Manuscripts from partnership follow agreed authorship rules; lead submits draft to named reviewers at least X days (commonly 30). <br> - Any public statement about partners or funders requires Communications Lead approval and agreed acknowledgement wording. <br> - Embargoes, IP-sensitive outputs, or donor-sensitive releases require joint sign-off per contract clause. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Financial controls linked to approvals:</strong> <br> - Payments are triggered only on approved deliverable acceptance. <br> - Change request with budget impact > threshold must have finance sign-off before release. <br> - Holdbacks or escrow (e.g., 10% retention) can be included to enforce deliverables. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Sample subject & email body for an approval request (copy-ready):</strong> <br> <strong>Subject:</strong> <code>Approval request — [EventCode] — [Short issue] — Reply by [YYYY-MM-DD]</code> <br> <strong>Body:</strong> <br>1) One-line ask: "Approve [action] — Owner — Due." <br>2) One-line rationale & impact.<br>3) Attachments: SOW, budget delta, risk note, prior approvals.<br>4) Recommendation & alternate.<br>5) "Please sign/approve in tracker or reply 'Approve — [Name]' by [date]." </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Signatures & acceptable evidence:</strong> <br> - Digital signatures (institutional e-sign) or signed PDF accepted; an approver's institutional email plus tracker entry is acceptable for low-risk approvals if policy allows. <br> - Legal and financial approvals must use institutional signatory formats per institution policy. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Operational examples (short vignettes)</strong> <br> - <strong>Budget reallocation £30k:</strong> WP lead prepares pack; PI + Finance approve within 7 days; Institutional Grants Office notified and posts approval in tracker. <br> - <strong>New subcontract £300k:</strong> proposal + DD pack → Legal + Finance + Institutional signatory → contract signed; funds released in tranches linked to milestones. <br> - <strong>Emergency protocol change in field:</strong> field lead escalates to PI by call; PI gives provisional approval; formal change request submitted within 48h for steering ratification. </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>KPIs for governance performance:</strong> <br> - % approvals completed within SLA. <br> - % approval requests with complete evidence pack on first submission. <br> - Number of retrospective approvals (indicator of governance gaps). <br> - Time from request to signed decision (median). </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Checklist to embed before executing approvals:</strong> <br> - Is the approver authorised for this value/risk? (Yes/No) <br> - Is the evidence pack complete? (Yes/No) <br> - Is the DSA/ethics needed and obtained? (Yes/No) <br> - Is the decision logged with IndexNo? (Yes/No) <br> - Are follow-on actions assigned and linked to payment triggers? (Yes/No) </td></tr><tr><td data-label="Why a contract is needed — improved operational guide (organized by your outline)"> <strong>Final operating rule (one-line):</strong> <br> "Require the minimum approvals needed to control risk — but always require enough evidence and trace to make the decision auditable." </td></tr></tbody></table></div><div class="row-count">Rows: 35</div></div><div class="table-caption" id="Table5" data-table="YJKN_0010_05" style="margin-top:2mm;margin-left:3mm;"><strong>Table 5</strong></div>
<div class="table-wrapper" data-table-id="table-5"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Intellectual property (IP) in research — operational guidance**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Intellectual property (IP) in research — operational guidance</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Definition (short):</strong> IP = legally or commercially protectable outputs from research (patents, copyright, database rights, designs, trade secrets, know-how, materials, trademarks). In research contexts IP management balances openness (scholarship) with protection (commercialisation, compliance, stewardship). </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Why IP matters for research projects:</strong> <br> - Protects downstream commercial value and incentivises translation. <br> - Clarifies ownership, preventing disputes that can delay publication or funding. <br> - Satisfies funder and institutional compliance (reporting, benefit-sharing). <br> - Enables controlled sharing (licenses, MTAs) that protect participants and data subjects. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Common IP types you will meet:</strong> <br> - <strong>Patents (inventions):</strong> new, inventive, industrially applicable technical inventions. <br> - <strong>Copyright:</strong> text, figures, software source code, slide decks, reports. <br> - <strong>Database rights / sui generis:</strong> curated datasets and structured collections. <br> - <strong>Designs & models:</strong> industrial designs, CAD models. <br> - <strong>Trade secrets / know-how:</strong> non-public methods, protocols, algorithms. <br> - <strong>Materials & biological samples:</strong> require MTAs. <br> - <strong>Trademarks & brand:</strong> project names, logos. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Background vs foreground IP (crucial distinction):</strong> <br> - <strong>Background IP:</strong> pre-existing IP contributed into the project (licence needed to use). <br> - <strong>Foreground IP:</strong> new IP created during the project (ownership must be assigned, licensed, or shared). <br> <strong>Practical:</strong> always capture a background inventory at project start and require partners to declare restrictions. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Who usually owns IP? (typical rules & variations)</strong> <br> - <strong>Employment / institutional policies:</strong> most universities assign invention ownership to the institution with revenue-share to inventors. <br> - <strong>Contract/funder rules:</strong> funder agreements may require specific ownership/licensing outcomes (open access, retained rights). <br> - <strong>Collaborations:</strong> joint ownership is possible but complex—prefer licensed arrangements or clear assignment rules. <br> - <strong>Small local partners / freelancers:</strong> confirm contractual assignment and signatory authority. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Joint ownership pitfalls (practical warnings):</strong> <br> - Joint ownership without clear licence rules leads to blocking rights and litigation risk. <br> - Avoid unspecified joint ownership; prefer: (a) one owner + cross-licence terms, or (b) defined field/territory/time licences. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Publication vs patent tension (essential operating rule):</strong> <br> - Public disclosure (conference, preprint, thesis) can destroy novelty for patents. <br> - Rule: disclose inventions to Technology Transfer Office (TTO) / IP lead BEFORE public disclosure. Use provisional filings to protect patentability while allowing time for publication planning. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Data, software & code (practical rules):</strong> <br> - Treat software as copyright + potential patent if it embodies a technical invention. <br> - Choose licences deliberately: permissive (MIT/BSD) vs copyleft (GPL) vs custom research licences. <br> - For datasets use clear data licences (e.g., CC0/CC BY/ODC-BY) and note funder open-access requirements. <br> - Maintain reproducible code, version control and clear contributor records for authorship/IP clarity. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Materials & biological samples (controls):</strong> <br> - Use Material Transfer Agreements (MTAs) to control use, restrictions, benefit sharing and IP arising from downstream use. <br> - Capture chain-of-custody, consent terms and local regulations for genetic resources (CBD / Nagoya principles may apply). </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Confidentiality & NDAs (when to use):</strong> <br> - Use NDAs only where necessary (commercial discussions, early tech disclosure). <br> - NDAs should be time-bounded, specify permitted disclosures and permit disclosure to institutional TTO under safe terms. Avoid NDAs that prevent publication by academics without clear exceptions. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Licensing models (how you can share IP):</strong> <br> - <strong>Non-exclusive licence:</strong> typical for research reuse, commercialization open to multiple licensees. <br> - <strong>Exclusive licence:</strong> one licensee for a field/territory — better monetisation but restricts research use. <br> - <strong>Field/territory/time-limited licences:</strong> balance revenue and academic freedom. <br> - <strong>Open licences (code/data):</strong> enable reuse and reproducibility; ensure contributor consent and no donor restrictions. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Revenue & benefit sharing (practical patterns):</strong> <br> - Institutional revenue share: standard university formula (inventor share + central reinvestment). <br> - Collaborative projects: pre-agree revenue splits, reinvestment into project/community and capacity building. <br> - For community or indigenous contributions plan benefit-sharing and prior informed consent. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>IP management workflow (operational steps)</strong> <br> 1) <strong>Identify</strong>: invention disclosure, code/data/material declarations during project lifecycle. <br> 2) <strong>Record</strong>: log in IP register with date, contributors, context. <br> 3) <strong>Assess</strong>: TTO/legal performs novelty, freedom-to-operate, and market/impact scan. <br> 4) <strong>Protect</strong>: patent filing, copyright registration, trade-secret controls, MTAs or NDAs as needed. <br> 5) <strong>Manage</strong>: assign steward (TTO), negotiate licences, subaward flow-downs. <br> 6) <strong>Commercialise / steward</strong>: license, spin-out or place in repository with stewardship plan. <br> 7) <strong>Close & archive</strong>: final reports, repository deposits, licensing records. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Contract clauses to include (practical shortlist)</strong> <br> - <strong>Ownership clause:</strong> background retained by contributor; foreground ownership rules (institutional ownership or assignment). <br> - <strong>Disclosure & patent filing clause:</strong> mandatory invention disclosure to TTO; publication hold duration for patent filing (e.g., 30 days). <br> - <strong>Licence grant clause:</strong> background licence to partners for project purposes; post-project licensing terms. <br> - <strong>Moral rights & authorship:</strong> recognition and review periods for manuscripts. <br> - <strong>Revenue sharing & reinvestment:</strong> splits and use of proceeds. <br> - <strong>MTA / DSA references:</strong> link to required MTAs/DSAs and SRE conditions. <br> - <strong>Termination & IP survivals:</strong> carve-outs preserving licensing rights post termination. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Sample short clause snippets (copy-ready)</strong> <br> - <strong>Invention disclosure:</strong> "Each Party will disclose inventions arising from the Project to its TTO within 10 business days of identification." <br> - <strong>Publication hold:</strong> "No public disclosure of a disclosed invention without prior written confirmation of patent filing; Parties shall use commercially reasonable efforts to file provisional application within 30 days." <br> - <strong>Background licence:</strong> "Each Party grants the others a royalty-free, non-exclusive licence to its Background IP solely to the extent necessary to perform the Project." </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Funder & ethical compliance (must-check items):</strong> <br> - Funders may require open access to research outputs or data sharing — align licence strategy. <br> - Human subject data demands consent for specific uses; consent forms must allow proposed licensing/sharing. <br> - Publicly funded research often expects non-exclusive access for follow-on research — negotiate IP terms accordingly. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Due diligence & risk checks (pre-award and pre-contract)</strong> <br> - Check background IP encumbrances and freedom-to-operate on core components. <br> - Verify institutional signatory authority for IP assignments. <br> - Confirm third-party licences in code or materials (open-source obligations). <br> - Identify export controls, sanctions or material transfer restrictions. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Open science vs commercialisation (practical balance):</strong> <br> - Decide early: where openness accelerates impact vs where protection is needed to create products/partners. <br> - Use staged approaches: provisional patent → targeted open dataset release → code under chosen OSS licence. <br> - Document rationale for choices in the Project IP Annex. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Ethics, benefit sharing & community IP concerns:</strong> <br> - For indigenous knowledge or community data incorporate PIC/MTAs, access committees, and benefit sharing clauses. <br> - Avoid extractive practises: ensure local partners have negotiated rights, capacity and co-authorship. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Record-keeping & KPIs (what to monitor)</strong> <br> - IP register entries (date, lead, type). <br> - Number of invention disclosures filed. <br> - Time from disclosure to patent filing. <br> - Licence agreements executed and revenue flows. <br> - Compliance: manuscripts cleared against invention disclosures before submission. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Practical checklist for PIs before public disclosure/presentation</strong> <br> - Have you declared any potential inventions to your TTO? (Yes/No) <br> - Are there third-party materials or code with licence obligations? (Yes/No) <br> - Does your funder require open data or specific licensing? (Yes/No) <br> - Is human-subject consent adequate for intended data sharing/licensing? (Yes/No) </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Negotiation tips & red flags</strong> <br> - <strong>Tip:</strong> Insist on project-purpose background licences rather than broad assignment of background IP. <br> - <strong>Tip:</strong> Limit publication review periods (30 days typical) and resist indefinite approval rights. <br> - <strong>Red flag:</strong> partner refuses any DSA/MTA or refuses to disclose background IP encumbrances. <br> - <strong>Red flag:</strong> clause that assigns all future IP from staff or students without exception — escalate to institutional legal. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Operational roles (who does what)</strong> <br> - <strong>PI / Inventor:</strong> declare, co-operate on description, do not publish before TTO review. <br> - <strong>TTO / Innovation Office:</strong> evaluate, file, negotiate licences, steward commercialization. <br> - <strong>Legal:</strong> draft/approve contract clauses, MTAs, NDAs. <br> - <strong>Data Custodian:</strong> implement DSA, SRE, access controls. <br> - <strong>Steering Group:</strong> decide strategic licensing or spin-out proposals per pre-agreed thresholds. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Case examples (short, practical)</strong> <br> - <strong>Patentable device:</strong> PI discloses prototype → TTO files provisional → partners agree field-limited exclusive licence for commercial partner, non-exclusive research licence retained for academia. <br> - <strong>Software & dataset:</strong> code released under MIT; dataset released under CC-BY with embargo for initial analysis by project partners; commercial use requires licence. </td></tr><tr><td data-label="Intellectual property (IP) in research — operational guidance"> <strong>Closing operational rule (one-line):</strong> <br> "Declare early, document background, protect only what needs protecting, and codify ownership/licence rules in the project IP Annex before signing anything." </td></tr></tbody></table></div><div class="row-count">Rows: 25</div></div><div class="table-caption" id="Table6" data-table="YJKN_0010_06" style="margin-top:2mm;margin-left:3mm;"><strong>Table 6</strong></div>
<div class="table-wrapper" data-table-id="table-6"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Why IP matters in collaborative research — concise operational guide**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Why IP matters in collaborative research — concise operational guide</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Purpose (short):</strong> IP determines who can use, publish, commercialise and steward research outputs. Clear IP rules prevent disputes, unlock translation, protect participants and make collaborations fundable and auditable. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Top reasons IP matters:</strong> <br> 1) <strong>Clarity of ownership:</strong> avoids later disputes that block publication, licensing or product development. <br> 2) <strong>Enables translation:</strong> protected IP (patents/licenses) makes commercial partners and investors willing to invest. <br> 3) <strong>Protects sensitive inputs:</strong> code, datasets, protocols, and biological materials need controls to protect subjects, comply with law, and respect consent. <br> 4) <strong>Allocates value & revenue:</strong> agreed splits and reinvestment plans avoid conflicts when revenue or spin-outs arise. <br> 5) <strong>Meets funders/institutional rules:</strong> many funders require explicit IP management and reporting. <br> 6) <strong>Manages publication vs patent tension:</strong> prevents accidental public disclosure that invalidates patents. <br> 7) <strong>Supports long-term stewardship:</strong> defines who maintains datasets, code and samples after project close. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Immediate collaboration impacts:</strong> <br> - <strong>Speed:</strong> unclear IP stalls decisions (who signs licence, who leads spin-out). <br> - <strong>Trust:</strong> vague IP terms breed mistrust, especially across unequal partners. <br> - <strong>Equity:</strong> failure to define benefit-sharing disadvantages local or community partners. <br> - <strong>Risk:</strong> inadvertent breach of third-party licences or export controls causes legal exposure. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Key IP concepts to settle early:</strong> <br> - <strong>Background IP:</strong> what partners bring in; declare restrictions and licence terms. <br> - <strong>Foreground IP:</strong> what the project creates; decide ownership, licensing and commercialisation roadmaps. <br> - <strong>Moral rights & authorship:</strong> recognition and review processes for publications. <br> - <strong>Confidential information / trade secrets:</strong> protection & access rules. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Immediate practical rules (operational):</strong> <br> 1) Inventory Background IP at kick-off. <br> 2) Require invention disclosure before any public presentation. <br> 3) Agree publication review window (typical: 30 days) tied to patent filing timelines. <br> 4) Use MTAs for material exchange and DSAs / SREs for sensitive data. <br> 5) Flow key IP/data clauses down to subs and vendors. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Why funders care (and so should you):</strong> <br> - Funders track outputs, open-access compliance, and benefit-sharing; unclear IP can impede payments and reporting. <br> - Demonstrable IP management increases credibility for translational funding. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Community & ethical considerations:</strong> <br> - Indigenous knowledge, community data and local samples need PIC, MTAs, and benefit-sharing clauses. <br> - Equitable IP arrangements (capacity, co-authorship, shared revenues) are essential for ethical partnerships. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Common failure modes (and fixes):</strong> <br> - <strong>Failure:</strong> party publishes before patent → <strong>Fix:</strong> mandatory TTO notification and provisional filing policy. <br> - <strong>Failure:</strong> joint ownership without licence rules → <strong>Fix:</strong> assign one steward + cross-licence terms by field/territory. <br> - <strong>Failure:</strong> background encumbrance undisclosed → <strong>Fix:</strong> background due-diligence checklist at negotiation. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Contract clauses to include (minimum):</strong> <br> - Background IP declaration & background licence for project purposes. <br> - Foreground ownership and commercialisation route (who decides to license/sell). <br> - Invention disclosure & publication hold period (e.g., 30 days). <br> - Licence permissions for research use after project end. <br> - Revenue-sharing & reinvestment rules. <br> - MTA/DSA reference and breach remedies. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Practical negotiation trade-offs:</strong> <br> - Prefer project-purpose non-exclusive background licences rather than broad assignments. <br> - Limit publication review windows; accept short holds for patent filings. <br> - Negotiate liability/indemnity proportionate to value and risk. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Operational roles (who does what):</strong> <br> - <strong>PI / inventor:</strong> disclose promptly, avoid public disclosure until cleared. <br> - <strong>TTO / Innovation Office:</strong> assess, file, negotiate licences, steward commercialization. <br> - <strong>Legal:</strong> draft/approve IP, MTA, NDA and revenue clauses. <br> - <strong>Data Custodian:</strong> implement DSAs and secure compute. <br> - <strong>Steering Group:</strong> decide strategic licensing or spin-out proposals per agreed thresholds. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Due diligence checklist for incoming partners:</strong> <br> - Background IP list and encumbrances? (Yes/No) <br> - Institutional signatory authority for IP assignments? (Yes/No) <br> - Any third-party licence obligations on code/materials? (Yes/No) <br> - Export controls or MTAs required? (Yes/No) </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Practical governance steps (copy-ready):</strong> <br> 1) Add an IP Annex to the collaboration agreement. <br> 2) Require invention disclosure form & PI acknowledgement. <br> 3) Set publication hold: notify TTO, file provisional patent if required, then release. <br> 4) Record licences and MTAs in project register. <br> 5) Review IP status at each milestone/quarterly. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>Example short clause snippets (copy-paste):</strong> <br> - <strong>Background licence:</strong> "Each Party grants the others a royalty-free licence to Background IP solely for Project performance." <br> - <strong>Disclosure & hold:</strong> "Inventors must disclose inventions to their TTO within 10 business days. No public disclosure until TTO confirms filing or waives hold (max 30 days)." <br> - <strong>Revenue split:</strong> "Net revenue from commercialisation will be split X% Institution A / Y% Institution B after costs; reinvest Z% into local capacity." </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>When to escalate to institutional counsel or TTO:</strong> <br> - Potential patentable inventions, complex ownership disputes, significant commercial interest, export-controlled technologies, or refusal to accept basic DSAs/MTAs. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>KPIs & record-keeping (what to monitor):</strong> <br> - IP register entries and status (disclosed, filed, licensed). <br> - Time from disclosure to filing. <br> - Number of MTAs/DSAs executed. <br> - Manuscripts checked vs disclosures before submission. </td></tr><tr><td data-label="Why IP matters in collaborative research — concise operational guide"> <strong>One-line operational rule:</strong> <br> "Set IP rules early: declare background, require disclosure before public disclosure, agree ownership/licensing and revenue rules, and log everything in the IP Annex." </td></tr></tbody></table></div><div class="row-count">Rows: 17</div></div><div class="table-caption" id="Table7" data-table="YJKN_0010_07" style="margin-top:2mm;margin-left:3mm;"><strong>Table 7</strong></div>
<div class="table-wrapper" data-table-id="table-7"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Who owns IP? — practical guide for research collaborations**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Who owns IP? — practical guide for research collaborations</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Short answer (practical):</strong> Ownership depends on (a) institutional policy (employment contracts), (b) funder rules, and (c) contract between partners. If not agreed in advance, institutions usually claim ownership of inventions created by their employees; collaborators normally retain their own background IP and negotiate foreground ownership/licences. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Core principle:</strong> Decide early, write it down. Ownership + licence terms must be explicit in the collaboration agreement or project contract before public disclosure or commercialisation actions. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Background vs Foreground:</strong> <br> <strong>Background IP:</strong> pre-existing IP contributed into the project (retained by contributor; usually licensed-in for project use). <br> <strong>Foreground IP:</strong> IP generated during the project (must be assigned/owned/licensed by contract). </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Typical institutional rules (common patterns):</strong> <br> - Universities and employers: own inventions by staff (policy); academics are inventors but institution owns patent rights and shares revenue via institutional policy. <br> - Independent consultants/contractors: usually retain IP unless contract assigns it to the client. <br> - Students: institution policies vary; funded projects often require assignment or licence clauses. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Who owns software & code?</strong> <br> - If written by employees in scope of employment → institution owns copyright. <br> - If written by students/contractors → ownership follows contract terms; use contributor license agreements or assignment clauses to clarify. <br> - Choose a licence (MIT/GPL/CC) early for reuse and clarity. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Biological materials & samples:</strong> <br> - Use MTAs. Ownership of physical samples differs from IP in derived inventions; MTAs define permitted uses and downstream IP/licence terms. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Joint ownership — pitfalls:</strong> <br> - Jointly owning patents or copyrights across institutions is legally complex; unilateral commercialisation often blocked unless explicit licence rules are set. <br> - Prefer: designate a steward (one owner) + cross-licence or field/territory/time-limited licence rather than undifferentiated joint ownership. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Assignment vs Licence (practical distinction):</strong> <br> - <strong>Assignment:</strong> ownership transferred (rare across institutions). <br> - <strong>Licence:</strong> grants use rights (preferred: exclusive/non-exclusive, field-limited, time-limited). For most collaborations, grant project-purpose licences to partners rather than assign background or foreground IP outright. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Patents vs publication (operational constraint):</strong> <br> - Public disclosure before filing destroys patentability. Require invention disclosure to TTO and a publication hold (e.g., 30 days) to allow provisional filing. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Funder rules & contractual overrides:</strong> <br> - Funders may require open access or data sharing—these can constrain exclusive licensing or commercial terms. Always map funder IP clauses and ensure contract compatibility. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Students, theses & supervision:</strong> <br> - Theses often count as public disclosure; require thesis embargo or TTO review if patentable inventions may arise. Clarify student IP ownership and revenue share in the project agreement. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Contractors & consultants:</strong> <br> - Use clear commissioning contracts: assign foreground IP or grant client an exclusive licence; require deliverables and source-code escrow where appropriate. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Third-party & open-source dependencies:</strong> <br> - Verify third-party licences (OSS) for viral obligations (GPL) that may force release; perform license due diligence before choosing licence strategy. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Commercial partners / industry collaborators:</strong> <br> - Industry often asks for exclusive rights; balance with academic openness by negotiating field-limited exclusivity, retained research rights, and fair revenue-share. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Materials Transfer Agreements (MTAs) & DSAs:</strong> <br> - Use MTAs for physical materials and DSAs for sensitive data; both should include downstream IP/license rules and publication/consent constraints. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Typical IP contract clauses (must-have):</strong> <br> - Background declaration & licence-in for project purposes. <br> - Foreground ownership rule (who owns what) and licence-back or access rights for partners. <br> - Invention disclosure & publication hold policy. <br> - Commercialisation decision process and revenue-sharing. <br> - Survivals: licences that survive termination. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Operational model options (pick one early):</strong> <br> 1) Institution-owned foreground + non-exclusive research licences to partners. <br> 2) Joint stewardship with clearly defined field/time-limited licences. <br> 3) Partner A owns foreground in field X; Partner B gets rights in field Y (territory/field carve-outs). </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Revenue & benefit-sharing (practical patterns):</strong> <br> - Pre-agree revenue splits, reinvestment rules (e.g., X% to local capacity), and admin deductions. Document distribution triggers (net after costs). </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Who decides on commercialisation?</strong> <br> - Define decision-makers and thresholds in contract (e.g., steering group decides up to stage £X; TTO handles licensing; PI/steering for spin-out proposals above threshold). </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>What to do before public disclosure or conference presentations:</strong> <br> - File invention disclosure with TTO. <br> - Pause public release until patent/filing decision or agreed waiver. <br> - If urgent, use provisional patent filing to protect novelty. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Due diligence checks for incoming partners:</strong> <br> - Background IP declared? Restrictions? Encumbrances? <br> - Institutional policy on employee inventions? <br> - Any existing licences that block planned use? </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Practical negotiation tips:</strong> <br> - Ask for project-purpose, royalty-free background licences rather than broad assignments. <br> - Limit exclusive licences by field/term/territory. <br> - Keep publication review windows short (30 days typical). <br> - Use escrow or staged exclusivity if funder/industry demands exclusivity. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Sample short clause snippets (copy-ready):</strong> <br> - Background licence: "Each Party grants the others a non-exclusive, royalty-free licence to Background IP to the extent necessary to perform the Project." <br> - Foreground ownership: "Foreground inventions shall be owned by [Institution A]; [Institution B] shall receive a non-exclusive licence for research use and a first option to negotiate commercial licence." <br> - Publication hold: "No public disclosure of an invention for 30 days after disclosure to TTO to permit filing." </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Record-keeping & register:</strong> <br> - Maintain an IP register: disclosures, dates, inventors, filings, licences, MTAs, DSAs, revenue flows and stewardship responsibility. Link to project archive and contract IndexNo. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Escalation & dispute path:</strong> <br> - Define faster internal mediation path (steering → PI → institutional legal/TTO → mediation/arbitration) and thresholds for escalation for ownership disputes. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Common red flags (escalate):</strong> <br> - Partner refuses to declare background IP. <br> - Partner asks to assign all staff/student future IP without limits. <br> - Refusal to accept reasonable DSA/MTA or to allow TTO review prior to publication. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Practical case examples (short):</strong> <br> - Multisite lab method: lab A's technique (background) licensed to consortium; foreground improvement patented by implementer with cross-licence to consortium for research. <br> - Software tool: code authored by multiple institutions → joint stewardship agreed, MIT licence for academic use, commercial licences managed by lead TTO. </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> <strong>Checklist for PIs before signing collaboration agreement:</strong> <br> - Background IP declared? (Yes/No) <br> - Foreground ownership rules clear? (Yes/No) <br> - Publication hold & TTO processes included? (Yes/No) <br> - Revenue-sharing & steward named? (Yes/No) <br> - MTAs/DSAs templates attached? (Yes/No) </td></tr><tr><td data-label="Who owns IP? — practical guide for research collaborations"> Decide ownership early, prefer licences over surprise assignments, protect patentable ideas before disclosure, and document everything in the IP Annex. </td></tr></tbody></table></div><div class="row-count">Rows: 29</div></div><div class="table-caption" id="Table8" data-table="YJKN_0010_08" style="margin-top:2mm;margin-left:3mm;"><strong>Table 8</strong></div>
<div class="table-wrapper" data-table-id="table-8"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Due diligence in IP management — operational guide**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Due diligence in IP management — operational guide</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Purpose (short):</strong> Verify IP provenance, encumbrances, ownership claims, freedom-to-operate, and downstream sharing/commercial constraints so contractual commitments are safe, auditable and actionable. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>When to run DD on IP:</strong> <br> - Before signing collaboration, licence, MTA, DSA, subcontract or commercial deal. <br> - Prior to public disclosure or conference presentations. <br> - Before accepting third-party code/material into your pipeline. <br> - When a commercial partner or investor requests IP certainty. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>High-level outcomes of good DD:</strong> <br> - Clear inventory of background IP and encumbrances. <br> - Freedom-to-operate risk assessment + mitigation plan. <br> - Confirmed authorised signatory for transfers/assignments. <br> - Contractual routes (licences, MTAs, assignment wording) ready to flow-down. <br> - Decision: Proceed / Proceed-with-conditions / Defer / Decline. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Scope — what to check (domains):</strong> <br> 1) Background IP inventory & licence terms. <br> 2) Foreground IP assignment policy (institutional). <br> 3) Publication/patent conflict & novelty risk. <br> 4) Third-party code/data licences (OSS compliance). <br> 5) MTAs, DSAs and consent terms for samples/data. <br> 6) Export control, sanctions & regulatory restrictions. <br> 7) Existing agreements, encumbrances, liens or exclusive licences. <br> 8) Staff/student/consultant agreements and inventor declarations. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Standard evidence pack to request (copy-ready):</strong> <br> - Background IP list (short inventory) + proof of ownership. <br> - Recent grant/contract templates that encumber background IP. <br> - Sample MTAs or licences previously used. <br> - Invention disclosure forms and any filed provisional patents. <br> - Source code repo links and dependency/licenses manifest (SBOM or license list). <br> - Data consent forms, DSA drafts, and SRE description. <br> - Student supervision & thesis embargo policies where relevant. <br> - Authorised signatory letter on institutional letterhead. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Freedom-to-Operate (FTO) practical check:</strong> <br> - Run a scoped patent landscape for core claims (internal or outsourced). <br> - Map whether core components implement third-party claims. <br> - If potential blocking patents found, record claim scope, jurisdictions and expiry and propose mitigation (design-around, licence, non-assertion, indemnity). </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Software & open-source checks:</strong> <br> - Gather dependency manifest (package-lock, requirements.txt). <br> - Identify viral licences (GPL, AGPL) and their implications. <br> - Confirm contributor agreements or CLA for external code. <br> - If accepting external code, require source provenance and confirm no licence conflicts with intended use (research vs commercial). </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Data & materials checks:</strong> <br> - Confirm consent covers intended reuse/commercialisation. <br> - Check Nagoya/CBD obligations for genetic resources. <br> - Validate MTAs for restrictions (derivatives, IP claims, commercial use). <br> - Ensure SRE meets access controls and export rules. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Ownership & assignment checks:</strong> <br> - Verify institutional policy re: employee inventions. <br> - Check student thesis/publication timelines and embargo options. <br> - For contractors: confirm signed IP assignment or work-for-hire clauses. <br> - Confirm transfer/assignment authority for signatories. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Third-party encumbrances & existing licences:</strong> <br> - Search for exclusive licences on core tech; request licence abstracts. <br> - Ask partner for list of prior agreements that could restrict fields/territories. <br> - If exclusivity exists, obtain copy and map fields/territories/durations. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Publication & patentability checkpoint:</strong> <br> - Require invention disclosure before any public talk/manuscript. <br> - If invention likely patentable, provisional filing or publication hold (typical 30 days) before public release. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Export control, sanctions & regulatory checks:</strong> <br> - Identify whether tech/data falls under dual-use, encryption, biological agents or restricted chemicals. <br> - Run sanctions/PEP checks on signatories. <br> - Flag cross-border transfer restrictions early. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Risk scoring (simple rubric):</strong> <br> - Score domains 1 (low) / 2 (medium) / 3 (high). <br> - Weight data/third-party licences higher where project depends on them. <br> - Aggregate to decision bands: <=1.4 accept; 1.5–2.0 accept-with-conditions; >2.0 escalate/defer/decline. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Mitigations and conditional controls:</strong> <br> - Staged funding / escrow / milestone holdbacks. <br> - Require partner to secure licence from third party before first tranche. <br> - Add indemnity for third-party IP claims (proportionate). <br> - Use field/territory/time-limited exclusivity to preserve research rights. <br> - Require code escrow for source and reproducibility. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Contract integration (what to flow into agreements):</strong> <br> - Background IP warranties & representations (limited to knowledge). <br> - Foreground ownership + licence-back rules. <br> - MTA/DSA annexes with permitted uses and SRE spec. <br> - OSS compliance obligations and export controls clause. <br> - Invention disclosure procedure & publication hold timing. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Red flags that should block or escalate:</strong> <br> - Refusal to disclose background IP or encumbrances. <br> - Undisclosed exclusive licences on core tech. <br> - No authorising signatory or unresolved institutional approval. <br> - OSS viral licence conflict for commercial intent. <br> - Data consents that forbid intended use. <br> - Export control sanctions or legal prohibitions. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Practical workflow (copy-ready):</strong> <br> 1) <strong>Scope & owner:</strong> assign DD Lead (legal/TTO + tech reviewer). <br> 2) <strong>Request evidence pack</strong> using standard checklist with 10-working-day deadline. <br> 3) <strong>Desk review</strong> (legal + tech) and initial red-flag list. <br> 4) <strong>Interviews</strong> with finance, PI, TTO, and code owner. <br> 5) <strong>FTO / patent scan</strong> (outsourced if needed). <br> 6) <strong>Risk score & recommendation:</strong> Accept / Accept-with-conditions / Defer / Decline. <br> 7) <strong>Write Decision Memo & conditions</strong> into contract annex; log in IP register. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Who to involve (roles):</strong> <br> - DD Lead (PM or legal). <br> - Technology Transfer Office (TTO) / IP Manager. <br> - Legal counsel (contract & export). <br> - Data custodian / SRE lead. <br> - Tech reviewer (senior engineer/scientist). <br> - Finance (for escrow/payment controls). </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Record-keeping & audit trail:</strong> <br> - Store evidence pack, interview notes, risk score and decision memo in contract folder with IndexNo. <br> - Link conditions to action tracker and payment triggers. <br> - Keep MTAs/DSAs and licence copies versioned. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Quick templates (copy-paste snippets)</strong> <br> - <strong>Evidence request email subject:</strong> <code>DD-IP request — [Partner] — [Project] — docs due [date]</code>. <br> - <strong>Minimal evidence list:</strong> "Please provide: 1) background IP list; 2) sample MTAs/DSAs; 3) recent invention disclosures; 4) source code licence manifest; 5) authorised signatory letter." <br> - <strong>Decision memo line:</strong> "Decision: Accept-with-conditions. Conditions: (1) OSS licence compliance report (owner) within 10 days; (2) SRE proof-of-security; (3) milestone holdback £X until condition 1 met." </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>KPIs & monitoring:</strong> <br> - % IP DD completed before signature. <br> - # red flags found per deal. <br> - Time from DD start to decision (median). <br> - % conditional mitigations closed before first payment. </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Short checklist for PIs before public disclosure or demo:</strong> <br> - Have you submitted an invention disclosure to TTO? (Yes/No) <br> - Are there third-party licence obligations in your code? (Yes/No) <br> - Is data consent compatible with planned sharing? (Yes/No) <br> - Is any material export-controlled? (Yes/No) </td></tr><tr><td data-label="Due diligence in IP management — operational guide"> <strong>Final one-line operational rule:</strong> <br> "Treat IP DD as fast, evidence-based triage: get identity, licences, consent and FTO clarity first; accept with conditions only if mitigations are funded, owned and logged." </td></tr></tbody></table></div><div class="row-count">Rows: 23</div></div><div class="table-caption" id="Table9" data-table="YJKN_0010_09" style="margin-top:2mm;margin-left:3mm;"><strong>Table 9</strong></div>
<div class="table-wrapper" data-table-id="table-9"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **Nagoya Protocol — concise operational briefing **"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>Nagoya Protocol — concise operational briefing </strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>What it is (short):</strong> An international agreement under the Convention on Biological Diversity that creates a framework for access to genetic resources and fair & equitable sharing of benefits arising from their use (ABS). It establishes obligations for users and providers and creates the ABS Clearing-House for transparency. :contentReference[oaicite:0]{index=0} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Scope — what it covers (practical):</strong> <br> • Genetic resources and associated traditional knowledge when used for research, development or commercialisation. <br> • Does <strong>not</strong> apply to human genetic resources. <br> • National implementing measures determine domestic scope, definitions and permit processes — so applicability depends on the provider country’s law. :contentReference[oaicite:1]{index=1} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Core legal requirements (plain language):</strong> <br> 1) <strong>Prior Informed Consent (PIC)</strong> — obtain permission from the provider (country or authorised body) before access where national law requires it. <br> 2) <strong>Mutually Agreed Terms (MAT)</strong> — negotiate and record benefit-sharing terms (monetary or non-monetary) in writing (contract). <br> 3) <strong>Compliance / check & report:</strong> users must be able to show due diligence and evidence that access complied with PIC & MAT (ABS Clearing-House and national checkpoints). :contentReference[oaicite:2]{index=2} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>ABS Clearing-House (what to use it for):</strong> <br> • Primary international registry for party measures, national contact points, checklists, and certificates of compliance. <br> • Use it to identify legal requirements and national focal points before any fieldwork or acquisition. :contentReference[oaicite:3]{index=3} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Digital Sequence Information (DSI) — current practical note:</strong> <br> • The Protocol’s material scope applies to <strong>physical</strong> genetic resources; DSI (digitised sequence data) has been debated at CBD COP processes and may be addressed by separate/parallel measures — check current negotiations and funder/national policy before relying on an exemption. :contentReference[oaicite:4]{index=4} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Why it matters for researchers (concrete impacts):</strong> <br> - Legal obligation to comply or face sanctions, withheld funding or reputational harm. <br> - Affects sample collection, export/import permits, data sharing, publication timing and collaborations. <br> - Non-compliance can block downstream commercialisation or journal acceptance if data provenance is required. :contentReference[oaicite:5]{index=5} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Practical due-diligence checklist for researchers (before fieldwork or acquiring materials):</strong> <br> 1) Check ABS Clearing-House for provider country measures and national focal point. :contentReference[oaicite:6]{index=6} <br> 2) Confirm whether the resource is within Nagoya scope (species, use, and country rule) and whether DSI rules affect your plan. :contentReference[oaicite:7]{index=7} <br> 3) Obtain PIC or confirm that access is permitted without PIC under national law. <br> 4) Negotiate MAT (written contract) specifying permitted uses, benefit-sharing, IP, authorship, capacity building, and commercial terms. <br> 5) Secure export/import permits and any institutional approvals (ethics, biosafety). <br> 6) Record everything: permit copies, PIC/MAT, correspondence; log in project’s ABS register. <br> 7) Use an MTA/DSA and ensure repository/SRE conditions for sensitive data. :contentReference[oaicite:8]{index=8} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>What to put in MAT (mutually agreed terms) — practical items:</strong> <br> - Exact resources covered and permitted uses (research only, commercial development, derivatives). <br> - Benefit-sharing mechanisms (monetary payments, capacity building, co-authorship, data access, technology transfer). <br> - IP handling and publication review windows linked to patent filing. <br> - Duration, territory, sub-licensing rights, and termination clauses. <br> - Practical clauses: sample disposal, data retention, dispute resolution, and contact points. :contentReference[oaicite:9]{index=9} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Record-keeping & evidence (what to archive):</strong> <br> - PIC documents, permit/authorisation, MAT/contract, certificates of compliance (where issued), MTAs/DSAs, export/import permits, and ABS CH references. <br> - Maintain project-level ABS register and link approvals to samples/data in lab records and data repositories. :contentReference[oaicite:10]{index=10} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Institutional steps (what universities / PIs should do):</strong> <br> - Implement Nagoya compliance policy and assign an ABS officer or legal contact. <br> - Provide project templates (PIC checklist, MAT template, MTA/DSA templates). <br> - Train researchers on due diligence and include ABS checks in ethics & funding approvals. :contentReference[oaicite:11]{index=11} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>If you get notified of non-compliance (immediate pragmatic actions):</strong> <br> 1) Stop use of the resource for new work until clarified. <br> 2) Contact institutional legal/TTO and national focal point. <br> 3) Attempt retroactive PIC/MAT if national law allows (some countries permit retroactive arrangements; others do not). <br> 4) Prepare remedial measures: benefit-sharing offers, cooperation and documentation to minimise penalties. :contentReference[oaicite:12]{index=12} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Common research pain-points & mitigations:</strong> <br> - <strong>Ambiguity on whether a use is covered:</strong> do conservative due diligence and consult the national focal point. :contentReference[oaicite:13]{index=13} <br> - <strong>Delays from permit processes:</strong> build time into project plan; consider pilot data or non-sensitive preparatory work. <br> - <strong>DSI and digital data uncertainties:</strong> track COP outcomes and funder instructions; when in doubt, treat DSI as sensitive for benefit-sharing discussions. :contentReference[oaicite:14]{index=14} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Sample clause snippets (copy-ready starters):</strong> <br> - <strong>PIC warranty:</strong> "Partner warrants that access to the material complied with provider country law and provides copies of PIC/permit." <br> - <strong>MAT clause:</strong> "Use restricted to [specified uses]; benefit-sharing to include [monetary/ non-monetary]; IP & publication procedures set out in Annex X." <br> - <strong>Record & audit:</strong> "Parties keep records for X years; audits on reasonable notice." </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Where to check & who to contact (authoritative resources):</strong> <br> - CBD Nagoya Protocol pages and full text (official treaty text & explanatory materials). :contentReference[oaicite:15]{index=15} <br> - ABS Clearing-House for national measures and certified information. :contentReference[oaicite:16]{index=16} <br> - National focal points and competent national authorities (listed on ABS CH). <br> - Institutional research/ethics office and Technology Transfer Office for MAT/IP guidance. :contentReference[oaicite:17]{index=17} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Quick operational checklist (one-page for field teams)</strong> <br> 1) ABS CH lookup & national focal point — record link. :contentReference[oaicite:18]{index=18} <br> 2) Confirm applicability (resource, use, country). :contentReference[oaicite:19]{index=19} <br> 3) Obtain PIC / written permit or confirm legal exemption. <br> 4) Sign MAT with clear benefit-sharing & IP terms. <br> 5) Issue MTA/DSA for transfers and SRE proof for data. <br> 6) Archive all documents in Project ABS Register. <br> 7) Re-check before publication, commercialization or cross-border transfer. :contentReference[oaicite:20]{index=20} </td></tr><tr><td data-label="Nagoya Protocol — concise operational briefing"> <strong>Bottom line (practical takeaway):</strong> <br> Treat Nagoya compliance as part of research design: check national rules early via the ABS Clearing-House, secure PIC & MAT where required, record everything, and embed ABS steps into ethics/funding workflows to avoid legal, financial and reputational risk. :contentReference[oaicite:21]{index=21} </td></tr></tbody></table></div><div class="row-count">Rows: 16</div></div><div class="table-caption" id="Table10" data-table="YJKN_0010_10" style="margin-top:2mm;margin-left:3mm;"><strong>Table 10</strong></div>
<div class="table-wrapper" data-table-id="table-10"><div class="table-heading-bar" aria-label="Table heading"></div><div class="table-container"><div class="table-header-wrapper" style="display:flex; justify-content:space-between; align-items:center; margin-bottom:5px;"><div class="copy-buttons"><button type="button" class="copy-plain-btn" data-action="copy-plain" onclick="copyTablePlain(this)">Copy Plain Table</button><button type="button" class="copy-markdown-btn" data-action="copy-markdown" onclick="copyTableMarkdown(this)">Copy Markdown Table</button><button type="button" class="export-csv-btn" data-action="export-csv" onclick="exportTableCSV(this)">Export CSV</button><button type="button" class="export-json-btn" data-action="export-json" onclick="exportTableJSON(this)">Export JSON</button><button type="button" class="export-xlsx-btn" data-action="export-xlsx" onclick="exportTableXLSX(this)">Export XLSX</button><button type="button" class="export-pdf-btn" data-action="export-pdf" onclick="exportTablePDF(this)">Export PDF</button><button type="button" class="export-markdown-btn export-markdown-initial" data-action="export-markdown" onclick="exportTableMarkdown(this)" style="display:none" data-initial-hidden="1">Export Markdown</button></div><div style="display:flex; align-items:center;"><button type="button" class="toggle-table-btn" data-action="toggle-collapse" onclick="toggleTable(this)">Collapse Table</button></div></div><table class="tv-table" role="table"><thead><tr><th class="tv-col-left" role="button" aria-label="Sort by **What IP could arise — mobile app, algorithm, dataset, training material, diagnostic method (practical map + protections &amp; contract actions)**"><div class="th-with-sort"><div style="flex:1; white-space:nowrap; overflow:hidden; text-overflow:ellipsis;"><strong>What IP could arise — mobile app, algorithm, dataset, training material, diagnostic method (practical map + protections & contract actions)</strong></div><button class="sort-btn sort-state-0" title="Toggle sort" aria-label="Toggle sort"><span class="sort-icon" aria-hidden="true"></span></button></div></th></tr></thead><tbody><tr><td data-label="What IP could arise — mobile app, algorithm, dataset, training material, diagnostic method (practical map + protections &amp; contract actions)"> <strong>Mobile app</strong> <br> <strong>IP that can arise:</strong> copyright in source code, compiled code and UI; design rights in UI/UX; trademark for app name/logo; patents on novel technical features (e.g., unique recommender, secure sync method); database rights for curated user data; trade secrets (behind-the-scenes architecture, keys). <br> <strong>Who typically owns:</strong> employer/institution by policy for staff; contractors if assignment/commissioning contract says so; collaborators per contract. <br> <strong>Protection & tech controls:</strong> code repository + contributor license agreements (CLAs); OSS licence audit; code escrow for commercial deals; trademark registration; patent provisional if novel; app-store compliance and privacy-by-design. <br> <strong>Contract clauses to include:</strong> background licence-in; foreground ownership or assigned licence; OSS compliance warranty; maintenance & update obligations; app-store revenue split; DPA/Privacy clauses; indemnities for third-party IP. <br> <strong>Immediate checklist:</strong> run OSS dependency scan; require CLA or assignment from contributors; record background software; draft DPA for user data; consider provisional patent if feature novel. </td></tr><tr><td data-label="What IP could arise — mobile app, algorithm, dataset, training material, diagnostic method (practical map + protections &amp; contract actions)"> <strong>Algorithm (ML/statistical method)</strong> <br> <strong>IP that can arise:</strong> patentable inventions (technical improvements, model architectures with technical effect); copyright in implementation code; trade secret/know-how (training regimen, hyperparameter schedules, data-prep pipelines); database rights in training data; possible sui generis rights in model weights under some regimes. <br> <strong>Who typically owns:</strong> institution via employment policy; contractors by assignment; collaborators per agreement. <br> <strong>Protection & controls:</strong> invention disclosure to TTO before disclosure; provisional patents where appropriate; NDAs for external reviews; internal access controls for model weights; source/code escrow for commercialisation. <br> <strong>Contract clauses to include:</strong> inventor disclosure process; publication hold tied to filing; licence-back for research use; export-control warranty; OSS/third-party licence indemnity. <br> <strong>Immediate checklist:</strong> declare potential inventions; embargo public release until TTO clears; document third-party model/data licences; plan FTO for core claims. </td></tr><tr><td data-label="What IP could arise — mobile app, algorithm, dataset, training material, diagnostic method (practical map + protections &amp; contract actions)"> <strong>Dataset</strong> <br> <strong>IP that can arise:</strong> database rights (EU-style), copyright in selection/arrangement, neighbouring rights; contractual rights by DSA; no-one owns raw facts but compilation and curation can be protected; consent and provenance constraints (Nagoya, human-subjects consent) impose legal limits. <br> <strong>Who typically owns / stewards:</strong> collecting institution or data custodian; data subjects retain privacy rights; community partners may have negotiated rights. <br> <strong>Protection & controls:</strong> DSA specifying permitted uses, access tiers, SRE requirements, register DOIs/metadata, anonymisation & provenance records; MTAs for biological samples. <br> <strong>Contract clauses to include:</strong> permitted uses, redistribution/derivative rules, re-identification prohibition, citation/attribution, benefit-sharing, retention and deletion, audit rights. <br> <strong>Immediate checklist:</strong> confirm consent and legal basis; check Nagoya/DSI and export rules; prepare DSA and SRE spec; attach provenance metadata and licences for derivatives. </td></tr><tr><td data-label="What IP could arise — mobile app, algorithm, dataset, training material, diagnostic method (practical map + protections &amp; contract actions)"> <strong>Training material (slides, modules, videos, curricula)</strong> <br> <strong>IP that can arise:</strong> copyright in text, slides, video/audio, images; moral rights and attribution; possibly trademark for course brand; database rights for assembled curricula. <br> <strong>Who typically owns:</strong> institution or author per contract; contractors/freelancers by assignment. <br> <strong>Protection & controls:</strong> choose and record an explicit licence (CC BY, CC BY-NC, proprietary), clear third-party content licences, maintain contributor agreements, embed attribution and reuse rules. <br> <strong>Contract clauses to include:</strong> assignment or licence terms, permitted reuse & derivative rights, attribution text, revenue sharing for paid courses, indemnities for third-party content. <br> <strong>Immediate checklist:</strong> clear contributor IP agreements; replace any unlicensed third-party assets; decide open vs restricted licence and record it in the contract. </td></tr><tr><td data-label="What IP could arise — mobile app, algorithm, dataset, training material, diagnostic method (practical map + protections &amp; contract actions)"> <strong>Diagnostic method (protocol, test, algorithmic diagnostic)</strong> <br> <strong>IP that can arise:</strong> patents for novel diagnostic methods/biomarkers (jurisdiction-dependent—some countries restrict patents on diagnostic methods or medical procedures); copyright in protocols/documents; trade secrets for proprietary thresholds/algorithms; regulatory data exclusivity issues. <br> <strong>Who typically owns:</strong> institution / employer; co-inventor rights in staff contracts; private partners via negotiated licences. <br> <strong>Protection & controls:</strong> early invention disclosure; consider patent protection where allowed; manage publication vs filing carefully; MTAs/DSAs for samples and clinical data; regulatory pathway & data collection plans. <br> <strong>Contract clauses to include:</strong> IP ownership & commercialisation route; clinical data ownership; indemnity and regulatory compliance clauses; revenue share and licensing field carve-outs; data-use and patient-consent alignment. <br> <strong>Immediate checklist:</strong> notify TTO before presentations; check national law on patentability for diagnostic methods; ensure consent covers commercial use and regulatory filings. </td></tr><tr><td data-label="What IP could arise — mobile app, algorithm, dataset, training material, diagnostic method (practical map + protections &amp; contract actions)"> <strong>Cross-cutting contract & operational recommendations (applies to all assets)</strong> <br> <strong>Standard clauses to insist on:</strong> <br> 1) Background IP inventory & licence-in. <br> 2) Foreground ownership/assignment or well-scoped licence. <br> 3) Invention disclosure & publication hold (30 days typical). <br> 4) OSS compliance & warranties. <br> 5) DSA/MTA annexes. <br> 6) Confidentiality & trade-secret protection. <br> 7) Indemnities for third-party IP claims. <br> 8) Escrow for source or models where commercial risk exists. <br> 9) Revenue-sharing and reinvestment rules. <br> <strong>Risk controls:</strong> <br> 1) Staged payments or escrow until due diligence is complete. <br> 2) Insurance and liability caps aligned to clinical/commercial risk. <br> 3) Field, territory, and time limits on exclusivity to preserve research use. <br> <strong>Practical checklist for negotiation & launch:</strong> <br> 1) Record background IP and third-party licences. <br> 2) Require CLAs or IP assignment from all contributors. <br> 3) Run OSS licence scans and freedom-to-operate checks for patentable claims. <br> 4) Draft and agree DSA/MTA and privacy/DPA documents. <br> 5) Decide and record licences for code, data, and training materials. <br> 6) File invention disclosures before any public demo or publication. <br> 7) Appoint an IP steward (TTO or data custodian) and log all assets in the IP register. </td></tr></tbody></table></div><div class="row-count">Rows: 6</div></div><script src="assets/xlsx.full.min.js?v=1758605028" defer></script>
<script src="assets/script.js?v=1759748863" defer></script>
<script src="assets/worker.js?v=1758331710" defer></script>
<script>
(function(){
  const template = "{table}_{date}";
  const userVal = "";
  const hrefPrefix = "assets";
  function formatName(tableName) {
    const date = (new Date()).toISOString().slice(0,10);
    return template.replace('{table}', tableName).replace('{date}', date).replace('{user}', userVal);
  }
  const btn = document.getElementById('exportBtn');
  if(btn) {
    btn.addEventListener('click', async function() {
      try {
        const html = document.documentElement.outerHTML;
        if(html.length > 2000000) { alert('Export refused: html too large'); return; }
        if(window.Worker) {
          const workerUrl = (function(){ try{ return hrefPrefix + '/worker.js'; }catch(e){ return null; } })();
          if(workerUrl) {
            try {
              const worker = new Worker(workerUrl);
              worker.postMessage({html: html, format: 'pdf'});
              worker.onmessage = function(e) { console.log('worker:', e.data); alert('Worker replied: '+(e.data.msg||e.data.status)); };
            } catch(err) { console.warn('Worker create failed', err); alert('Worker not available'); }
          } else { alert('Worker not available'); }
        } else { alert('Export worker not supported in this environment.'); }
      } catch(err) { console.warn('Export failed', err); alert('Export worker not available. See console for details.'); }
    });
  }
})();
window.addEventListener('load', function(){ try{ document.querySelectorAll('.table-wrapper').forEach(function(e){ e.style.opacity='1'; }); }catch(e){} });
</script>
</div>
</body>
</html>